This week in drug discovery (21-25 October)
News round-up for 21-25 October by DDW Senior Digital Content Editor Diana Spencer.
With a presidential election just round the corner in the US and a new UK budget on the way, financial support for life sciences is high on the agenda, so the news round-up this week focuses on investment in drug discovery, by private investors, governments and charities.
The top stories:
Pfizer supports antibody for peripheral arterial disease
UK-based biotechnology company IsomAb has announced the nomination of a development candidate for peripheral arterial disease (PAD), therapeutic antibody ISM-001.
Calls for life sciences and new medicines support in UK Budget
With a new UK Budget looming on 30 October, the first of this new Labour government, the Chancellor has been urged to protect the country’s life sciences sector and increase investment in medicines.
World-first precision trial boosts drug discovery for brain cancer
Cancer Research UK and Australian charity the Minderoo Foundation have committed £3 million to a clinical study designed to find better treatments for brain cancer.
Sanofi and Orano invest in potential of radioligand cancer medicines
Sanofi and Orano Med have entered into an agreement with the aim of accelerating the development of radioligand medicines.
AvenCell raises $112 million for switchable CAR-T cell therapies
AvenCell Therapeutics has raised $112 million in Series B financing to support the development of both autologous and allogeneic switchable CAR-T cell therapies.